Prospective, prospective, multicentre, double-blind, randomised, multi-centre study of three parallel groups of patients:~Group 1 (n=15): standard of care + C1 inhibitor~Group 2 (n=15): standard care + icatibant + C1 inhibitor~Group 3 (n=15): standard support + placebo~The study has two parts:~A 4-day (96-hour) therapeutic part during which the patient will be evaluated nine times (H0, H4, H12, H24, H36, H48, H60, H72 and H96).~A follow-up part of 6 days with at least two assessments (D7 and D10).~The maximum duration of patient participation in the study will be 10 days.
The main objective of this study is to evaluate the efficacy of human C1 inhibitor, administered alone or in combination with icatibant (a specific bradykinin B2 receptor antagonist) on the pulmonary manifestations of COVID-19 infections.